ANVS - Why Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday? | Benzinga
Annovis Bio Inc (NASDAQ:ANVS) shares plunged after the company released data from its Phase 2/3 Alzheimer study of buntanetap in mild to moderate Alzheimer’s patients.
Investors are reacting as during the trial, ADCS-CGIC in all groups of patients barely changed, with no statistically significant difference observed.
The 15mg and 30mg buntanetap groups slightly improved in mild Alzheimer’s patients.
The ADCS-CGIC is a clinician-rated measure of global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
The company also observed a large placebo effect in ADCS-ADL, with 15mg and 30mg buntanetap groups showing similar improvements with no statistical difference between the groups.
The ADCS-ADL is an informant-rated measure of functional impairment scored from 0 to 78, ...